Phase I trial to assess the safety and tolerability of PVX108 in peanut allergic adults
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs PVX108 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Aravax
- 24 Apr 2018 The protocol has been amended to reduce number of administrations required to demonstrate safety of repeat administration in Stage 2.
- 24 Apr 2018 Planned End Date changed from 9 May 2018 to 30 Nov 2018.
- 22 May 2017 New trial record